NANOBIOTIX Statement Regarding Recent Media Speculation
Rhea-AI Summary
NANOBIOTIX (NASDAQ: NBTX) issued a statement on March 25, 2026 addressing recent media speculation about a potential public take-over.
The company said, to its knowledge, there is no intention by any party to acquire control and no process or assessment is underway; it also identified factual inaccuracies in the report that conflict with its recent public disclosures.
Positive
- Company denial of takeover intentions on March 25, 2026
- No process or assessment toward acquisition reported
Negative
- Media report contained factual inaccuracies versus company disclosures
News Market Reaction – NBTX
On the day this news was published, NBTX gained 4.65%, reflecting a moderate positive market reaction. Argus tracked a peak move of +8.5% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $71M to the company's valuation, bringing the market cap to $1.61B at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
NBTX was down 4.16% while close biotech peers showed a mixed pattern: BCYC up 5.51%, REPL up 0.43%, ERAS up 1.14%, and ARCT/OPT down 1.34%/2.01%. This points to stock-specific dynamics around the clarification of takeover speculation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Capital structure update | Neutral | +4.9% | Updated disclosure of shares outstanding and voting rights under French rules. |
| Feb 25 | Investor conferences | Neutral | +1.4% | Announcement of management participation in several March investor conferences. |
| Feb 17 | Capital structure update | Neutral | +1.1% | Monthly disclosure of shares outstanding and theoretical vs exercisable voting rights. |
| Jan 13 | Capital structure update | Neutral | +0.7% | Report on December 31, 2025 share count and total voting rights per regulations. |
| Dec 17 | Capital structure update | Neutral | +3.1% | Disclosure of November 30, 2025 voting rights and share capital under AMF rules. |
Recent disclosures on share capital and investor engagement have generally coincided with modest positive price reactions.
Over the last few months, Nanobiotix has mainly released routine updates on voting rights, share capital, and participation in investor conferences. Filings on December 17, 2025, January 13, 2026, February 17, 2026, and March 12, 2026 detailed incremental changes in shares outstanding and voting rights, each followed by small positive moves. An additional February 25, 2026 announcement highlighted upcoming investor conferences. Today’s statement fits into this pattern of corporate communications clarifying the company’s capital and strategic visibility.
Market Pulse Summary
This announcement addressed recent media speculation by stating that, to the company’s knowledge, there was no intention or ongoing process to acquire control. It also highlighted factual inconsistencies versus prior public disclosures. In context of recent updates on voting rights and investor conferences, the news highlights continued emphasis on transparency. Investors would typically watch future regulatory filings, capital-structure notices, and any subsequent strategic announcements for confirmation of this stance.
Key Terms
nanotherapeutic medical
public take-over financial
AI-generated analysis. Not financial advice.
PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today issued the following statement in response to recent media speculation concerning intentions for a potential public take-over.
Nanobiotix states that, to the best of its knowledge, there is no such intention to acquire control of the Company, and no process or assessment is being conducted toward that end. Additionally, the Company has identified factual inaccuracies in this media report which are not consistent with the Company’s most recent public disclosures.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Disclaimer
This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 2, 2025 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2024 universal registration document filed with the AMF on April 2, 2025 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2025 filed on September 30, 2025 which are available on the SEC’s website at www.sec.gov and on the AMF's website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.
Communications Department
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com
Attachment
- 2026-03-25 -- NBTX -- Statement Regarding Recent Media Rumor -- FINAL
FAQ
Does NANOBIOTIX (NBTX) face a takeover bid as of March 25, 2026?
What exactly did NANOBIOTIX (NBTX) deny in its March 25, 2026 statement?
How should investors interpret NANOBIOTIX's (NBTX) March 25, 2026 clarification?
Did NANOBIOTIX (NBTX) announce any financial transactions alongside the March 25, 2026 statement?
Will NANOBIOTIX (NBTX) provide further updates after its March 25, 2026 statement?
